Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
about
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsTumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated AutophagySOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
P2860
Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differential PAX5 levels promo ...... patients independent of CCND1.
@en
type
label
Differential PAX5 levels promo ...... patients independent of CCND1.
@en
prefLabel
Differential PAX5 levels promo ...... patients independent of CCND1.
@en
P2093
P2860
P356
P1433
P1476
Differential PAX5 levels promo ...... patients independent of CCND1.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2015.140
P577
2015-06-15T00:00:00Z
P6179
1042163462